Skip to main content
See who owns your news
Get Started
SubscribeLogin
Published • loading... • Updated

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO - Regional Media News

Summary by regionalmedianews.com
Oct 20 (Reuters) - Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO market. The South San Francisco, California-based company is seeking to raise [...]

2 Articles

regionalmedianews.comregionalmedianews.com
Lean Right

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO - Regional Media News

Oct 20 (Reuters) - Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO market. The South San Francisco, California-based company is seeking to raise [...]

Read Full Article
endpoints.newsendpoints.news

Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO

Pfizer halts Phase 2 autoimmune trial: The study was testing a program called PF-06835375 in the rare autoimmune disorder primary immune thrombocytopenia. The federal clinical trials database noted the halt was ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

regionalmedianews.com broke the news on Tuesday, October 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Initial Public Offering (IPO) icon

Initial Public Offering (IPO)

South San Francisco icon

South San Francisco

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal